Latest Insider Transactions at Talaris Therapeutics, Inc. (TALS)
This section provides a real-time view of insider transactions for Talaris Therapeutics, Inc. (TALS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Talaris Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Talaris Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2022
|
Nancy Krieger Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.5%
|
-
|
|
Sep 10
2022
|
Mary Kay Fenton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+49.69%
|
-
|
|
Aug 22
2022
|
Suzanne Ildstad Director |
SELL
Open market or private sale
|
Direct |
525,000
-14.56%
|
$1,050,000
$2.8 P/Share
|
|
Jul 29
2022
|
Scott Requadt |
BUY
Open market or private purchase
|
Direct |
39,382
+7.19%
|
$157,528
$4.25 P/Share
|
|
Jul 28
2022
|
Scott Requadt |
BUY
Open market or private purchase
|
Direct |
3,090
+0.65%
|
$12,360
$4.25 P/Share
|
|
Jul 26
2022
|
Scott Requadt |
BUY
Open market or private purchase
|
Direct |
5,528
+1.17%
|
$22,112
$4.24 P/Share
|
|
Jul 25
2022
|
Francois Nader Director |
BUY
Other acquisition or disposition
|
Indirect |
138,500
+26.36%
|
-
|
|
Jul 25
2022
|
Francois Nader Director |
SELL
Other acquisition or disposition
|
Direct |
138,500
-100.0%
|
-
|
|
Jul 22
2022
|
Scott Requadt |
BUY
Open market or private purchase
|
Direct |
9,444
+2.01%
|
$28,332
$3.75 P/Share
|
|
Jul 21
2022
|
Francois Nader Director |
BUY
Open market or private purchase
|
Direct |
36,500
+20.86%
|
$109,500
$3.72 P/Share
|
|
Jul 21
2022
|
Francois Nader Director |
BUY
Other acquisition or disposition
|
Indirect |
248,432
+50.0%
|
-
|
|
Jul 21
2022
|
Francois Nader Director |
SELL
Other acquisition or disposition
|
Indirect |
248,432
-73.9%
|
-
|
|
Jul 20
2022
|
Francois Nader Director |
BUY
Open market or private purchase
|
Direct |
52,000
+33.77%
|
$156,000
$3.62 P/Share
|
|
Jul 19
2022
|
Francois Nader Director |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$150,000
$3.52 P/Share
|
|
Dec 31
2021
|
Michael Zdanowski Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,470
+50.0%
|
$19,110
$13.0 P/Share
|
|
Dec 31
2021
|
Mary Kay Fenton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
$13,000
$13.0 P/Share
|
|
Dec 31
2021
|
Scott Requadt |
BUY
Grant, award, or other acquisition
|
Direct |
1,470
+0.32%
|
$19,110
$13.0 P/Share
|
|
Dec 15
2021
|
Francois Nader Director |
SELL
Bona fide gift
|
Indirect |
59,520
-15.04%
|
-
|
|
Nov 17
2021
|
Suzanne Ildstad Director |
BUY
Bona fide gift
|
Indirect |
1,200,000
+50.0%
|
-
|
|
Nov 17
2021
|
Suzanne Ildstad Director |
SELL
Bona fide gift
|
Direct |
1,200,000
-24.97%
|
-
|
|
May 11
2021
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
30,000
+0.42%
|
$510,000
$17.0 P/Share
|
|
May 11
2021
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
8,059,315
+33.25%
|
-
|
|
May 11
2021
|
Clarus Defined Exit I, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
30,000
+0.42%
|
$510,000
$17.0 P/Share
|
|
May 11
2021
|
Clarus Defined Exit I, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
8,059,315
+33.25%
|
-
|
|
May 11
2021
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
235,000
+6.8%
|
$3,995,000
$17.0 P/Share
|
|
May 11
2021
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,985,775
+50.0%
|
-
|
|
May 11
2021
|
Sandip Agarwala Director |
BUY
Open market or private purchase
|
Indirect |
235,000
+6.8%
|
$3,995,000
$17.0 P/Share
|
|
May 11
2021
|
Sandip Agarwala Director |
BUY
Conversion of derivative security
|
Indirect |
2,985,775
+50.0%
|
-
|